Tags

Type your tag names separated by a space and hit enter

Preventive measures and new pharmacological approaches of calcium and phosphate disorders.
Contrib Nephrol. 2008; 161:234-239.CN

Abstract

Abnormalities of bone mineral parameters (calcium, phosphate, vitamin D, and parathyroid hormone) are nearly omnipresent in patients with advanced chronic kidney disease (CKD). These typically consist of hypocalcemia, hyperphosphatemia, abnormalities of vitamin D metabolism, and secondary hyperparathyroidism (SHPT). Currently, several lines of evidence suggest that these abnormalities may have consequences beyond the typical consequence of renal bone disease, with a major role in determining cardiovascular disease, including arterial calcification. The 'classical' treatment of SHPT and hyperphosphatemia in HD patients consists of phosphate binders, vitamin D receptor activators (VDRAs), and/or calcimimetics. Calcium- or aluminum-based phosphate binder prescriptions and calcitriol administration are therapeutic tools not free of complications, increasing the risk of cardiovascular calcification in the HD population. New calcium- and aluminum-free phosphate binders, such as lanthanum carbonate and sevelamer hydrochloride, new VDRA (paricalcitol), and cinacalcet hydrochloride can be used to treat SHPT, slow down the atherosclerotic process, and prevent vascular calcification in HD patients.

Links

Publisher Full Text

Authors+Show Affiliations

Cozzolino M
Chair and Division of Nephrology, University of Milan, S. Paolo Hospital, Milan, Italy.
Galassi A
No affiliation info available
Pasho S
No affiliation info available
Fallabrino G
No affiliation info available
Gallieni M
No affiliation info available
Brancaccio D
No affiliation info available

MeSH

CalciumChronic DiseaseCinacalcetHumansHyperparathyroidism, SecondaryKidney DiseasesLanthanumNaphthalenesPhosphatesPolyaminesRenal DialysisSevelamerVitamin D

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18451682

Clinical Trial Links

Reduce Cardiovascular Calcifications to Reduce QT Interval in Dialysis

Citation

Cozzolino, Mario, et al. "Preventive Measures and New Pharmacological Approaches of Calcium and Phosphate Disorders." Contributions to Nephrology, vol. 161, 2008, pp. 234-239.
Cozzolino M, Galassi A, Pasho S, et al. Preventive measures and new pharmacological approaches of calcium and phosphate disorders. Contrib Nephrol. 2008;161:234-239.
Cozzolino, M., Galassi, A., Pasho, S., Fallabrino, G., Gallieni, M., & Brancaccio, D. (2008). Preventive measures and new pharmacological approaches of calcium and phosphate disorders. Contributions to Nephrology, 161, 234-239. https://doi.org/10.1159/000130696
Cozzolino M, et al. Preventive Measures and New Pharmacological Approaches of Calcium and Phosphate Disorders. Contrib Nephrol. 2008;161:234-239. PubMed PMID: 18451682.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Preventive measures and new pharmacological approaches of calcium and phosphate disorders. AU - Cozzolino,Mario, AU - Galassi,Andrea, AU - Pasho,Sabina, AU - Fallabrino,Guditta, AU - Gallieni,Maurizio, AU - Brancaccio,Diego, PY - 2008/5/3/pubmed PY - 2008/7/30/medline PY - 2008/5/3/entrez SP - 234 EP - 239 JF - Contributions to nephrology JO - Contrib Nephrol VL - 161 N2 - Abnormalities of bone mineral parameters (calcium, phosphate, vitamin D, and parathyroid hormone) are nearly omnipresent in patients with advanced chronic kidney disease (CKD). These typically consist of hypocalcemia, hyperphosphatemia, abnormalities of vitamin D metabolism, and secondary hyperparathyroidism (SHPT). Currently, several lines of evidence suggest that these abnormalities may have consequences beyond the typical consequence of renal bone disease, with a major role in determining cardiovascular disease, including arterial calcification. The 'classical' treatment of SHPT and hyperphosphatemia in HD patients consists of phosphate binders, vitamin D receptor activators (VDRAs), and/or calcimimetics. Calcium- or aluminum-based phosphate binder prescriptions and calcitriol administration are therapeutic tools not free of complications, increasing the risk of cardiovascular calcification in the HD population. New calcium- and aluminum-free phosphate binders, such as lanthanum carbonate and sevelamer hydrochloride, new VDRA (paricalcitol), and cinacalcet hydrochloride can be used to treat SHPT, slow down the atherosclerotic process, and prevent vascular calcification in HD patients. SN - 0302-5144 UR - https://www.unboundmedicine.com/medline/citation/18451682/Preventive_measures_and_new_pharmacological_approaches_of_calcium_and_phosphate_disorders_ L2 - https://www.karger.com?DOI=10.1159/000130696 DB - PRIME DP - Unbound Medicine ER -